Oxford University in the United Kingdom has been targeting people under the age of 17 until further information is available after reports of cases of blood clots being confirmed after vaccination with a new coronavirus vaccine developed with AstraZeneca. It has been revealed that clinical trials will be suspended.
Regarding the vaccine developed by Oxford University in collaboration with AstraZeneca, cases of blood clots confirmed after adult vaccination have been reported in various European countries.
Oxford University has started a clinical trial in the UK in February to see if people under the age of 17 can be included in the vaccination, but announced on the 6th that it will be suspended.
The university emphasized in a statement that "there are no concerns about the safety of clinical trials," and in response to reports of cases such as blood clots in rare cases, clinical trials are available until further information is obtained from regulators. The test is not proceeding.
EU regulators are continuing to investigate the vaccine in March, saying that "a safe and effective vaccine, the benefits of protecting people outweigh the risks," and will soon announce the results. It is a prospect.